§01 Browse › ACP-105

ACP-105

ACP-105
Mild Suppression
Pharmacology detail: animal ratings

These ratios are not measured human benefit or safety rankings.

Anabolic / Androgenic
80 6
13.3:1 vs testosterone baseline
Aromatizes No
Hepatotoxic No
Oral Yes
Suppression mild
PCT Usually no

This profile covers ACP-105. Compare the ingredient, formulation and evidence with compounds you already recognize, then read the risks.

Technical catalog description

ACP-105 is a mild non-steroidal SARM used for gradual recomp, training feel, joint comfort, and sometimes a more energized mood.

It is not a dramatic size or strength compound. It fits users who value tolerability over maximum output.

Overview Use context Comparison Safety
Warning
Early research – human data scarce · Long-term effects unknown

Read next

Beyond Testosterone and Deca: Comparing Steroid Families 3 min readHormones, the HPTA, and Suppression 8 min readThe Philosophy and Practice of Harm Reduction 9 min read
More depthSARMs, Prohormones, and Novel Compounds
Overview
Mechanism details

ACP-105 is a mild, non-steroidal SARM used for mood, training feel, joint comfort, and gradual recomp rather than major size or dramatic strength. Compared with heavier SARMs, the reports usually describe less obvious suppression and less aggressive dryness.

ACP-105 fits users who want to understand the lighter end of the SARM spectrum without pretending it is harmless. It still acts through androgen-receptor signaling, still has sourcing uncertainty, and can still affect lipids or endogenous hormones.

The compound is sometimes described as having a nootropic or energized feel. That is anecdotal, but it is part of why users choose it over Ostarine when they want something that feels more noticeable without jumping to RAD-140.

Safety & monitoring
Side effects

  • Natural suppression with reduced fertility and testicular output

  • Suppression, worsened lipids, and an evidence base that is much thinner than users assume

Monitoring

  • CBC / hematocrit

  • blood pressure

  • lipid panel

Avoid if

  • Uncontrolled hypertension or untreated cardiovascular disease

  • Pre-existing severe infertility concerns unless that risk is accepted and managed

Use context

ACP-105 is chosen for mild recomp, training quality, and cautious first exposure to SARM-style androgen-receptor drugs. It fits users who value tolerability more than maximum output.

It can also be used when joint comfort matters. Unlike dry DHT-derived steroids, ACP-105 is not known for a classic joint-drying feel.

Timeline & expectations

Expect subtle changes: better training consistency, mild strength improvement, and gradual body-composition change. If the goal is rapid visible transformation, ACP-105 is the wrong tool.

Because user experience is thinner than Ostarine, the run needs enough baseline control to interpret. Adding it to a crowded stack defeats the point.

Common mistakes

The main mistake is expecting mild compounds to overcome weak training or diet. ACP-105 is not strong enough to rescue a poorly built plan.

Another mistake is using “mild” as an excuse to skip bloodwork. Mild does not mean biologically inactive.

Comparison notes

Compared with Ostarine, ACP-105 is similarly mild but often described as more energizing.

Compared with LGD-4033, ACP-105 is much less mass-oriented and usually less suppressive.

Compared with RAD-140, ACP-105 is less aggressive, less dry, and less likely to satisfy users chasing obvious strength jumps.

Record quantities in the builder Read: Beyond Testosterone and Deca: Comparing Steroid Families ← Browse